(2,3-dimethyl-4H-furo[3,2-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone | 668480-18-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡咯
• 英文名称: (2,3-dimethyl-4H-furo[3,2-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone
• 英文别名: (2,3-dimethyl-4H-furo[3,2-b]pyrrol-5-yl)-(4-methylpiperazin-1-yl)methanone
• CAS: 668480-18-0
• 化学式: C₁₄H₁₉N₃O₂
• 分子量: 261.324
• InChiKey: BXYDILQMFNVRFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Heterocyclic compounds
  申请人：——

  公开号：US20040048878A1

  公开（公告）日：2004-03-11

  Certain thienopyrrolyl and furanopyrrolyl compounds are disclosed as useful to treat or prevent disorders and conditions mediated by the histamine H 4 receptor, including allergic rhinitis.

  某些噻吡咯基和呋咯咯基化合物被披露为治疗或预防由组胺H4受体介导的疾病和症状，包括过敏性鼻炎。
• Heterocyclic Compounds
  申请人：Cai Hui

  公开号：US20070185120A1

  公开（公告）日：2007-08-09

  Certain thienopyrrolyl and furanopyrrolyl compounds are disclosed as useful to treat or prevent disorders and conditions mediated by the histamine H 4 receptor, including allergic rhinitis.

  某些噻吩吡咯基和呋喃吡咯基化合物被披露为用于治疗或预防由组胺H4受体介导的疾病和症状，包括过敏性鼻炎。
• Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders
  申请人：Desmadryl Gilles

  公开号：US20120039913A1

  公开（公告）日：2012-02-16

  The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.

  该发明涉及组胺H4受体拮抗剂或组胺H4受体基因表达抑制剂，用于治疗和/或预防前庭障碍。
• Histamine H4 receptor antagonists for the treatment of vestibular disorders
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP2201982A1

  公开（公告）日：2010-06-30

  The invention relates to a Histamine H4 receptor antagonist or an inhibitor of Histamine H4 receptor gene expression for the treatment and/or the prevention of a vestibular disorder.

  本发明涉及一种组胺 H4 受体拮抗剂或组胺 H4 受体基因表达抑制剂，用于治疗和/或预防前庭失调症。
• SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3130376A1

  公开（公告）日：2017-02-15

  The invention relates to Histamine H4 receptor antagonists or inhibitors of Histamine H4 receptor gene expression for the treatment and/or the prevention of vestibular disorders.

  本发明涉及组胺 H4 受体拮抗剂或组胺 H4 受体基因表达抑制剂，用于治疗和/或预防前庭失调。